精确瘤学与选择性RET抑制剂selpercatinib在RET重新安排的癌症中的精确瘤学
Mohamed A Gouda1, Vivek Subbiah2
1Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center. Houston, TX, USA.
Therapeutic advances in medical oncology
|June 26, 2023
概括
在转移过程中重新排列的 (RET) 变化通过促进细胞增殖驱动癌症. 选择性RET抑制剂,如selpercatinib,为RET驱动的癌症提供了一种新的精确疗法,包括NSCLC和甲状腺癌.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 精准医学是一门精准的医学.
背景情况:
- 在转染过程中重新排列 (RET) 是一种编码受体氨酸激酶的原原体基因.
- 激活RET变异,包括融合和突变,在各种癌症中驱动不受控制的细胞增殖.
- RET变化与非小细胞肺癌 (NSCLC),甲状腺癌和其他恶性瘤有关.
研究的目的:
- 审查选择性RET抑制剂塞尔珀卡提尼布的当前状态.
- 讨论塞尔珀卡提尼布在RET融合阳性NSCLC和甲状腺癌中的疗效.
- 为了强调selpercatinib的组织不可知活性和FDA批准.
主要方法:
- 对RET抑制剂的临床试验和文献的审查.
- 对不同类型癌症中RET变化的流行情况的数据分析.
- 评估selpercatinib的临床结果和FDA的批准.
主要成果:
- 瘤性RET融合发生在约2%的NSCLC和10-20%的甲状腺癌中.
- RET突变是零星和遗传性髓性甲状腺癌的关键驱动因素.
- 塞尔珀卡提尼布已经证明了显著的疗效,并获得了FDA对RET改变的瘤的批准,包括组织无关的指示.
结论:
- 选择性RET抑制剂,如塞尔珀卡丁尼布,代表了精确瘤学的重大进步.
- 塞尔珀卡提尼布为RET融合阳性NSCLC,甲状腺癌和其他RET改变的恶性瘤患者提供了向治疗选择.
- 塞尔珀卡提尼布的成功强调了识别RET变化的重要性,以指导癌症治疗.
更多相关视频
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
1.1K
10:35A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction
Published on: April 5, 2018
10.4K
相关概念视频
02:57Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
02:50Combination Therapies and Personalized Medicine
5.0K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K
01:20The Retinoblastoma Gene
4.1K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.1K